Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus

Athanasia K. Papazafiropoulou, Marina S. Kardara and Stavros I. Pappas
3rd Department of Internal Medicine and Center of Diabetes, General Hospital of Nikaia “Ag. Panteleimon” – Piraeus, Greece

1. Introduction

Type 2 diabetes mellitus (T2DM) is increasing in prevalence worldwide, and is expected to affect 440 million people by 2030 (IDF, 2009). Despite the development and use of several medications to control patients’ blood glucose levels, the effective management of T2DM continues to be a challenge to physicians. In order to achieve HbA1c targets (<7.0%), patients must reach desirable fasting (90 mg/dL - 130 mg/dL) and postprandial glucose levels (<180 mg/dL) (American Diabetes Association, 2006). However, two thirds of patients with T2DM remain unable to reach the HbA1c targets (Koro, 1988; Fan, 2006).

Blood glucose levels are dependent on the dynamic processes of hepatic production of glucose and skeletal muscle use of glucose. Treatment strategies designed to improve these processes have as a result the improvement in patient’s glycemic status. Different agents are currently available, providing physicians with several options for the management of T2DM. These clinical therapies include insulin and oral drugs that are classified as insulin sensitizers (e.g., biguanides and thiazolidinediones), insulin secretagogues (e.g., sulfonylureas and meglitinides), and alpha-glucosidase inhibitors. Newer treatment agents, incretin mimetics and dipeptidyl peptidase 4 (DPP-4) inhibitors, have been recently added to clinicians’ therapeutic choices (Drucker, 2003; Drucker, 2006a).

2. The incretin effect

The concept that gut factors stimulate pancreatic endocrine secretion was hypothesized soon after secretin was discovered in 1902 (Kieffer, 1999). In 1906, this notion was tested by giving gut extracts to patients with diabetes, which reduced their glycosuria (Moore, 1906). In the 1920s, based on studies in dogs, the term incretins was introduced for the gastrointestinal hormones released in response to food ingestion (Zunz, 1929). These hormones are responsible for approximately 60% of the insulin secretion following a meal and for the so-called incretin effect. The incretin effect describes the phenomenon that oral glucose leads to
a greater insulin response than an isoglycaemic intravenous glucose load (McIntyre, 1964; Nauck, 1986).

There are two major incretins: glucosedependent insulinothropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). In this chapter we will focus on GLP-1 actions, since this molecule is preserved in patients with T2DM.

3. Physiological actions of GLP-1

GLP-1 is a product of the glucagons gene, which is expressed in pancreatic α-cells and in L-cells, located mostly in the lower small intestine and colon. GLP-1 concentrations increase as early as 5 to 10 minutes following ingestion of carbohydrates and lipids, well before the nutrients pass into the lower gut where most L-cells are located (Eissele, 1992; Deacon, 1995). Once released from L-cells, GLP-1 is rapidly metabolized by a widely distributed serine protease, DPP-4, resulting in a half-life of 1 to 2 minutes in the circulation. DPP-4, which is located on endothelial cells as well as in soluble form in plasma, cleaves the two N-terminal amino acids from GLP-1, causing a substantial loss of insulinotropic activity (Deacon, 1995; Vahl, 2003).

GLP-1 stimulates insulin secretion of the β-cells and inhibits glucagon secretion from the α-cells. Both actions occur in a glucose-dependent manner and lead to a normalisation of postprandial and fasting hyperglycaemia (Drucker, 2006b). In the gastrointestinal tract, GLP-1 has a direct effect on motility and slows gastric emptying. This effect contributes to a normalisation of postprandial hyperglycaemia and explains why long-term treatment with GLP-1 receptor agonists leads to weight loss (Drucker, 2006b). Under hypoglycaemic conditions the counter-regulation by glucagon is not affected and insulin secretion is not stimulated and, therefore, GLP-1 does not elicit hypoglycaemia (Drucker, 2006b). Except for its antidiabetic actions, recent findings have shown that application of GLP-1 receptor agonists led to an improvement in cardiovascular parameters (reduction of systolic blood pressure, beneficial effects on myocardial ischaemia in animal models, positive effects on left ventricular function in heart failure) (Papazafiropoulou, 2011). In addition, animal studies in rodents and isolated human islets showed beneficial long-term actions of GLP-1 to β-cell mass (Fehmann, 1992; Brubaker, 2004). Whether these findings will have a positive effect on preventing T2DM progression is not known yet.

4. Incretins and the pathogenesis of T2DM

In T2DM patients the incretin effect is diminished. Incretins does not act as an insulinothropic hormones under chronic hyperglycaemia in T2DM. However, GLP-1 is still able to stimulate insulin secretion under hyperglycaemia in T2DM (Drucker, 2006). In addition, the effects of GLP-1 on gastric emptying and glucagon secretion are maintained in patients with T2DM (Nauck, 1993a). A study confirmed that the incretin effect is reduced in patients with T2DM (Knop, 2007). Another study showed a significant reduction in the incretin effect and the GLP-1 response to oral glucose in T2DM patients compared with individuals with normal or impaired glucose tolerance (Muscelli, 2008). Notably, impaired actions of GLP-1 may be partially restored by improved glycemic control (Knop, 2007). The findings from a study of obese diabetic mice suggest that the effect of GLP-1 therapy may be caused by improvements in β-cell function and insulin sensitivity, as well as by a reduction in gluconeogenesis in the liver (Lee, 2007).
Several studies in T2DM patients have shown that synthetic GLP-1 administration induces insulin secretion, (Nathan, 1992; Nauck, 1993a) slows gastric emptying, and decreases inappropriately elevated glucagons secretion (Nauck, 1993a; Kolterman, 2003). Acute GLP-1 infusion studies showed that GLP-1 improved fasting and post prandial plasma glucose concentrations (Nathan, 1992; Nauck, 1993b). Long-term studies showed that this hormone exerts euglycemic effects, leading to improvements in HbA1c, and induces weight loss (Zander, 2002).

5. T2DM and incretin-based therapies

The incretin-based therapies offer a good alternative choice to the established antidiabetic compounds due to their satisfying antihyperglycaemic efficacy, their lack of risk of hypoglycaemia and their positive effects on body weight. In order to utilise GLP-1 action for T2DM, two options are presently available:

1. GLP-1-receptor agonists (or GLP-1 mimetics) as injectable compounds
2. DPP-4 inhibitors as orally active substances

6. GLP-1-receptor agonists

6.1 Exenatide

Exenatide is the synthetic form of exendin-4, a peptide first discovered in the saliva of the gila monster (Heloderma suspectum) in 1992. It has a 53% amino acid sequence homology to human GLP-1 and is a GLP-1 receptor agonist (Eng, 1992). It is administered subcutaneously twice daily. A slow release formulation for once-weekly administration (Exenatide LAR [long-acting release]) is presently in clinical phase III studies (Drucker, 2008). Exenatide has a prolonged half-life in comparison to native GLP-1 of approximately 3.5 h. After subcutaneous injection sufficient plasma concentrations are reached for 4–6 hours (Kolterman, 2005).

In clinical studies exenatide lowered the HbA1c by 0.8–1.1% (Buse, 2004; DeFronzo, 2005). Exenatide in combination with metformin (Kendall, 2005), sulfonylurea (DeFronzo, 2005), or both (Buse, 2004) resulted in significant mean HbA1c reductions from baseline ranging from -0.77% to -0.86%. Patients also had statistically significant reductions in mean body weight from baseline (-1.6 kg to -2.8 kg). Comparative studies with insulin showed that effects of exenatide on glycaemic parameters are comparable to the improvement seen with insulin therapy (Heine 2005; Gallwitz, 2006; Barnett, 2007; Nauck, 2007). The comparative studies with insulin showed a difference in weight development of 4–5 kg in 30 weeks between the insulin and exenatide treated groups (Heine 2005; Barnett, 2007a; Nauck, 2007a).

An improvement of β-cell function [measured with HOMA-β (homeostatic modelling assessment of beta cell function) and the proinsulin: insulin ratio] was also observed in the clinical studies. First phase of insulin secretion was restored after an intravenous glucose bolus under treatment with exenatide (Gallwitz, 2006; Barnett, 2007b).

Severe hypoglycaemic events were only observed in exenatide-treated patients who had received combination therapy with sulfonylurea. For this reason a reduction in the dosage of sulfonylurea should be considered when initiating exenatide therapy. In the comparative studies comparing exenatide with insulin treatment, the incidence of nocturnal hypoglycaemic events was lower in the exenatide-treated patients (Gallwitz, 2006; Barnett, 2007).
The most frequent adverse events with exenatide were fullness and nausea. Nausea was the most common reason to stop therapy; with 2–6.4% drop-outs in the clinical studies with exenatide (Gallwitz, 2006; Barnett, 2007). Escalating the dose of exenatide from 5 μg to 10 μg after 4 weeks led to a transient increase in nausea which diminished with continued exposure to the higher dose (Gallwitz, 2006; Barnett, 2007).

In approximately 40% of exenatide-treated patients, anti-exenatide antibodies can be detected. However, over a time period of at least 3 years, these antibody titres did not have any obvious effect on glycaemic control (Drucker, 2008). Cases of acute pancreatitis have been reported since exenatide has been used (Ahmad, 2008; Cure, 2008). In total, the incidence of pancreatitis was low and similar to the elevated risk of pancreatitis that was observed in obese T2DM patients (Dore, 2009).

Exenatide is predominantly eliminated by glomerular filtration followed by proteolytic degradation (Yoo, 2006). Exenatide should not be used in patients with severe renal impairment (creatinine clearance <30 ml/min) or end stage renal disease. Additionally, caution should be applied when initiating or increasing doses of exenatide in patients with moderate renal impairment (creatinine clearance 30–50 ml/min) (Gallwitz, 2006; Barnett, 2007).

### 6.2 Liraglutide

Liraglutide is the first human GLP-1 analogue. It has two modifications in the amino acid sequence of native GLP-1 and an attachment of a fatty acid side chain to the peptide. It is injected subcutaneously once daily (Agerso, 2002). Liraglutide lowers blood glucose, body weight and food intake in animal models (Sturis, 2003). In clinical studies in approximately 4,200 T2DM patients liraglutide was efficacious and safe (Marre, 2009; Nauck, 2009; Zinman, 2009). In animal studies with diabetic rodents, liraglutide has been shown to increase β-cell mass.

Liraglutide in monotherapy in newly diagnosed T2DM patients led to HbA1c reduction of 0.9–1.1% in a dose of 1.2 or 1.8 mg once daily respectively, over a period of up to 2 years (Garber, 2008). In other studies, the same doses of liraglutide effectively lowered glycaemic parameters in various combinations with oral antidiabetic agents by approximately 1.0–1.5% (Garber, 2008; Garber, 2009).

Liraglutide treatment led to a significant weight loss (Deacon, 2009a; Vilsboll, 2009). The weight loss was accompanied by a more pronounced loss in visceral fat than subcutaneous fat (Deacon, 2009a; Vilsboll, 2009). Furthermore, systolic blood pressure was lowered by 2–6 mmHg in the liraglutide-treated patients. This effect was independent of the weight loss, as the reduction of blood pressure was already observed early on in therapy, when weight loss had not yet occurred (Garber, 2008; Garber, 2009; Zinman, 2009).

The incidence of hypoglycaemic episodes was comparable to placebo in all studies, where no sulfonylurea was used in the combination with liraglutide (Deacon, 2009a; Vilsboll, 2009). Gastrointestinal symptoms were also common, but nausea and vomiting were reported for a short period at the beginning of therapy (Buse, 2009). In the liraglutide clinical trials, there was no evidence of neutralizing antibodies (Garber, 2008; Garber, 2009; Zinman, 2009).

Animal studies showed that a rare type of thyroid cancer known as medullary thyroid cancer was associated with liraglutide in mice and rats, although the relevance of this finding to humans remains unknown. FDA has stipulated that liraglutide be contraindicated in patients...
with a personal or family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 (US Food and Drug Administration, 2010). Data on the pharmacokinetic profile of liraglutide in mild to moderate renal impairment showed no alteration of the profile (Deacon, 2009a; Vilsboll, 2009).

7. DPP-4 Inhibitors

7.1 Sitagliptin

Sitagliptin was the first DPP-4 inhibitor approved for the T2DM treatment. The recommended dose of once-daily oral sitagliptin is 100 mg. At this dose, sitagliptin can inhibit ~80% of endogenous DPP-4 activity over a 24-hour period (Herman, 2005). Increases in HOMA-β ranging from 4% to 20% have been shown in the sitagliptin trials.

In the monotherapy trials, sitagliptin compared to placebo, resulted in statistically significant improvements in HbA1c and fasting glucose (Aschner, 2006; Raz, 2006; Scott, 2007). Sitagliptin given as add-on therapy to metformin (Charbonnel, 2006) resulted in similar HbA1c and fasting glucose reductions as in the monotherapy trials. The same result was observed, in a 24-week trial, when sitagliptin was added to pioglitazone vs pioglitazone and placebo (Rosenstock, 2006). In another study, reductions from baseline in HbA1c and fasting glucose were similar when sitagliptin was compared to glipizide, (Nauck, 2007). Increases in HOMA-β ranging from 4% to 20% have been shown in the sitagliptin trials.

Sitagliptin therapy has been shown to be weight neutral in all clinical trials except in one study in which sitagliptin given with metformin resulted in weight reduction of 1.5 kg after 52 weeks of treatment (Nauck, 2007b). The most common side effects of sitagliptin were headache, arthritis, nasopharyngitis, respiratory or urinary tract infections and rarely skin reactions (Aschner, 2006; Raz, 2006; Rosenstock, 2006). The incidence of hypoglycemia was low in these trials (<2%) and was similar to the placebo arms. Dose reduction of sitagliptin has been recommended for patients with moderate or severe renal insufficiency or end stage renal disease (Bergman, 2007).

7.2 Vildagliptin

Vildagliptin also acts by inhibiting circulating DPP-4 activity. It is available as a 50 mg twice-daily in combination with metformin, sulfonylurea or pioglitazone. Vildagliptin has been studied as monotherapy (Ristic, 2005; Pratley, 2006; Dejager, 2007), in combination with other oral antidiabetic agents (Ahren, 2004; Fonseca, 2007; Rosenstock, 2007), and against active comparator therapies including glitazones (Rosenstock, 2007) and metformin (Schweizer, 2007) Vildagliptin therapy was associated with an increase in HOMA-β (11% and 23%) in two monotherapy trials (Ristic, 2005; Pratley, 2006). In placebo-controlled trials, vildagliptin monotherapy reduced HbA1c (range 0.5% to 0.9%) and fasting glucose (14.4 mg/dL to 19.8 mg/dL) from baseline. The HbA1c reductions observed with monotherapy were statistically significantly greater than placebo in all trials. In clinical studies testing vildagliptin in monotherapy or combination therapy with metformin, glimepiride, pioglitazone or insulin, vildagliptin was able to decrease the HbA1c by approximately 0.5–1.0% (Ahren, 2008; Pratley, 2008; Barnett, 2009). Vildagliptin therapy was associated with an increase HOMA-β (11% and 23%) in two monotherapy trials (Ristic, 2005; Pratley, 2006), but improvement relative to placebo was only observed in one trial (Ristic, 2005).
Vildagliptin has a good safety and tolerability profile and the most common adverse events are flu-like symptoms, headache, dizziness, and rarely liver enzyme elevations. Vildagliptin, like the other DPP-4 inhibitors, is weight-neutral. The incidence of hypoglycemia was low in trials with vildagliptin and similar to the placebo (Fonseca, 2007; Rosenstock, 2007). No dose adjustment is required in patients with mild renal impairment (creatinine clearance ≥50 ml/min). Vildagliptin should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase or aspartate aminotransferase >3x the upper limit of normal.

7.3 Saxagliptin
Saxagliptin also acts by inhibiting circulating DPP-4 activity and is available as a 5 mg once-daily in combination with metformin, sulfonylurea or pioglitazone. Saxagliptin causes a reduction in HbA1c by 0.7–0.9%. Fasting plasma glucose is also lowered dose dependently lowered by saxagliptin (Rosenstock, 2008). In a study with drug-naïve patients, saxagliptin lowered all glycaemic parameters significantly (Rosenstock, 2009). As an add-on medication to a therapy with either metformin or glitazone, saxagliptin also led to significant metabolic improvements (Chacra, 2009; Deacon, 2009b; DeFronzo, 2009).

Saxagliptin did not cause hypoglycaemia, was well-tolerated and was weight-neutral. A meta-analysis of clinical phase III studies with saxagliptin showed favourable data on the development of cardiovascular events (Wolf, 2009).

8. In conclusion
Incretin-based therapies offer an alternative treatment option for T2DM patients by targeting pancreatic β-cell dysfunction. Both GLP-1 receptor agonists and DPP-4 inhibitors have been shown to be effective in improving glycemic control in patients with T2DM. They appear to be well tolerated, have a low risk of hypoglycaemia, lead to weight reduction or have a neutral effect on weight.

Choice of therapy should be based on a patient’s profile and preference, with consideration given to the unique characteristics of the GLP-1 receptor agonists and DPP-4 inhibitors. The most patient-relevant and striking difference between the incretin-based therapies is that GLP-1 receptor agonists are injectable agents, while DPP-4 inhibitors are effective orally. GLP-1 receptor agonists offer more robust HbA1c level reductions and the potential for weight loss. Nausea, the most common adverse event observed with GLP-1 receptor agonist therapy is not observed in treatment with DPP-4 inhibitors. Advances in the investigation of incretin therapies will further improve treatment outcomes for patients with T2DM and help them reach target goals.

9. References
Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M (2002). The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. *Diabetologia*, 45,195–202
Ahmad SR, Swann J (2008). Exenatide and rare adverse events. *N Engl J Med*, 358,1970–1971
Ahren B (2008). Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. *Expert Opin Emerg Drugs*, 13, 593–607

www.intechopen.com
Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus

American Diabetes Association (2006). Diagnosis and classification of diabetes mellitus. *Diabetes Care*, 29(Suppl 1), S43-S48

Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE (2006). Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care*, 29, 2632-2637

b. Barnett A (2007) Exenatide. *Expert Opin Pharmacother*, 8, 2593–2608

Barnett AH (2009). New treatments in type 2 diabetes: a focus on the incretin-based therapies. *Clin Endocrinol (Oxf)*, 70, 343–353

a. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME (2007). Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clin Ther*, 29, 2333–2348

Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA (2007). Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. *Diabetes Care*, 30, 1862-1864

Brubaker PL, Drucker DJ (2004). Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. *Endocrinology*, 145, 2653–2659

Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care*, 27, 2628–2635

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*, 374, 39–47

Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R (2009). Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with titration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. *Int J Clin Pract*, 63, 1395–1406

Charbonnel B, Karasik A, Liu J, Wu M, Meiningger G (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care*, 29, 2638-2643

Cure P, Pileggi A, Alejandro R (2008). Exenatide and rare adverse events. *N Engl J Med*, 358, 1969-1970

a. Deacon CF (2009). Potential of liraglutide in the treatment of patients with type 2 diabetes. *Vasc Health Risk Manag*, 5, 199–211

b. Deacon CF, Holst JJ (2009). Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. *Adv Ther*, 26, 488–499

Deacon CF, Johnsen AH, Holst JJ (1995). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. *J Clin Endocrinol Metab*, 80, 952–957

DeFronzo RA, Hisa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS (2009). The efficacy and safety of saxagliptin when added to metformin therapy in
patients with inadequately controlled type 2 diabetes with metformin alone. 
*Diabetes Care, 32, 1649-1655*

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005). Effects of 
exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-
treated patients with type 2 diabetes. *Diabetes Care, 28, 1092-1100*

Dejager S, Razac S, Foley JE, Schweizer A (2007). Vildagliptin in drug-naive patients with 
type 2 diabetes: a 24-week, doubleblind, randomized, placebo-controlled, multiple-
dose study. *Horm Metab Res, 39, 218-223*

Dore DD, Seeger JD, Arnold Chan K (2009). Use of a claimsbased active drug safety 
surveillance system to assess the risk of acute pancreatitis with exenatide or 
sitagliptin compared to metformin or glyburide. *Curr Med Res Opin, 25,1019-1027*

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L (2008).
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a 
randomised, openlabel, non-inferiority study. *Lancet, 372, 1240-1250*

Drucker DJ, Nauck MA (2006). The incretin system: glucagonlike peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet, 368, 1696–
1705*

b. Drucker DJ, Nauck MA (2006). The incretin system: glucagon-like peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet, 368, 1696–
1705*

Drucker DJ (2003). Enhancing incretin action for the treatment of type 2 diabetes. *Diabetes 
Care, 26, 2929-2940*

a. Drucker DJ (2006). Incretin-based therapies: a clinical need filled by unique metabolic 
effects. *Diabetes Educ, 32(Suppl 2), 65S-71S*

Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B (1992). Glucagon-
like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. 
*Eur J Clin Invest, 22, 283-291*

Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992). Isolation and characterization of 
exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further 
evidence for an exendin receptor on dispersed acini from guinea pig pancreas. *J Biol 
Chem, 267, 7402-7405*

Fan T, Koro CE, Fedder DO, Bowlin SJ (2006). Ethnic disparitiesand trends in glycemic 
control among adults with type 2 diabetes in the U.S. from 1988 to 2002. *Diabetes 
Care, 29, 1924-1925*

Fehmann HC, Habener JF (1992). Insulinotropic hormone glucagon-like peptide-1(7–37) 
stimulation of proinsulin gene expression and proinsulin biosynthesis in 
insulinoma beta TC-1 cells. *Endocrinology, 130,159–166*

Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S (2007). Addition of 
vildagliptin to insulin improves glycaemiccontrol in type 2 diabetes. *Diabetologia, 
50, 1148-1155.*

Gallwitz B (2006). Exenatide in type 2 diabetes: treatment effects in clinical studies and 
animal study data. *Int J Clin Pract, 60,1654–1661*

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olera-Alvarez I, 
Hale PM, Zdravkovic M, Bode B (2008). Liraglutide versus glimepiride 
monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase 
III, double-blind, parallel-treatment trial. *Lancet, 373, 473–481*
Garber A, Henry RR, Ratner RE, Hale P, Chang CT, Bode B (2009). Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in HbA1C, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. *Diabetes*, 58(Suppl 1), 162, OR

Heine RJ, van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (2005). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med*, 143, 559–569

Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. *Clin Pharmacol Ther*, 78, 675-688

International Diabetes Federation (IDF) (2009). Diabetes Atlas. Available at http://www.diabetesatlas.org

Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD (2005). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care*, 28,1083–1091

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T (2007). Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? *Diabetes*, 56, 1951–1959

Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y Baron AD (2003). Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. *J Clin Endocrinol Metab*, 88, 3082–3089

Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD (2005). Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. *Am J Health Syst Pharm*, 62, 173–181

Koro CE, Bowlin SJ, Bourgeois N, Fedder DO (2004). Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. *Diabetes Care*, 27,17-20

Lee YS, Shin S, Shigihara T, Hahn E, Liu MJ, Han J, Yoon JW Jun HS (2007). Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. *Diabetes*, 56, 1671–1679

Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). *Diabet Med*, 26, 268–278

McIntyre N, Holdsworth CD, Turner DS (1964). New interpretation of oral glucose tolerance. *Lancet*, 41, 20–21

Moore B, Edie E, Abram J (1906). On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. *Biochem J*, 1, 28–38
Muscelli E, Mari A, Casolaro A, Camasta S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E (2008). Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. *Diabetes*, 57, 1340–1348

Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992). Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. *Diabetes Care*, 15, 270–276

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR (2009). Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care*, 32, 84–90

A. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M (2007). A comparison of twicedailyexenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. *Diabetologia*, 50, 259–267

A. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J Clin Invest*, 91, 301–307

Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. *J Clin Endocrinol Metab*, 63, 492–498

B. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993). Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. *Diabetologia*, 36, 741–744

B. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, gliptide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab*, 9, 194–205

Papazafiropoulou A, Pappas S, Papadogiannis D, Tentolouris N (2011). Cardiovascular Effects of Glucagon-like Peptide 1. *Mini Rev Med Chem*, 11, 97-105

Pratley RE (2008). Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. *Medscape J Med*, 10, 171

Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D (2006). Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. *Horm Metab Res*, 38, 423-428

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitorsavigliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia*, 49, 2564-2571.

Retterstol K (2009). Taspoglutide: a long acting human glucagonlike polypeptide-1 analogue. *Expert Opin Investig Drugs* 18, 1405–1411

Ristic S, Byiers S, Foley J, Holmes D (2005). Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. *Diabetes Obes Metab*, 7, 692-698
Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus

Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R (2009). Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. *Curr Med Res Opin*, 25, 2401-2411

Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S (2007). Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. *Diabetes Obes Metab*, 9, 175-185

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*, 28, 1556-1568

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M (2009). The potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. *Diabetes Care*, 32, 1880-1886

Rosenstock J, Sankoh S, List JF (2008). Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. *Diabetes Obes Metab*, 10, 376–386

Scott R, Wu M, Sanchez M, Stein P (2007). Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. *Int J Clin Pract*, 61, 171-180

Sturis J, Gottfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB (2003). GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. *Br J Pharmacol*, 140:123–132

US Food and Drug Administration. Questions and answers—safety requirements for Victoza (liraglutide). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm198543.htm. Accessed August 9, 2010.

Vahl TP, Paty BW, Fuller BD, Prigeon RL, D’Alessio DA (2003). Effects of GLP-1-(7-36) NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. *J Clin Endocrinol Metab*, 88, 1772–1779

Vilsboll T (2009). Liraglutide: a new treatment for type 2 diabetes. *Drugs Today (Barc)*, 45, 101–113

Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S (2008). Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic β-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. *Diabet Med*, 25,152–156

Werner U (2008). Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. *Ann Endocrinol (Paris)*, 69, 164–165

Wolf R, Frederich R, Fiedorek FT, Donovan M, Xu Z, Harris S, Chen R (2009). Evaluation of CV risk in the saxagliptin clinical trials. *Diabetes*, 59(Suppl 1), 8

Yoo BK, Triller DM, Yoo DJ (2006). Exenatide: a new option for the treatment of type 2 diabetes. *Ann Pharmacother*, 40, 1777–1784
Zander M, Madsbad S, Madsen JL, Holst JJ (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet*, 359, 824–830

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdavkovic M, Blonde L (2009). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care*, 32,1224–1230

Zunz E, La Barre J (1929). Contributions à l’étude des variations physiologiques de la sécrétion interne du pancréas: relations entre les sécrétions externe et interne du pancréas. *Arch Int Physiol Biochim*, 31, 20–44
Over the last few decades the prevalence of diabetes has dramatically grown in most regions of the world. In 2010, 285 million people were diagnosed with diabetes and it is estimated that the number will increase to 438 million in 2030. Hypoglycemia is a disorder where the glucose serum concentration is usually low. The organism usually keeps the serum glucose concentration in a range of 70 to 110 mL/dL of blood. In hypoglycemia the glucose concentration normally remains lower than 50 mL/dL of blood. Hopefully, this book will be of help to many scientists, doctors, pharmacists, chemicals, and other experts in a variety of disciplines, both academic and industrial. In addition to supporting researcher and development, this book should be suitable for teaching.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Athanasia K. Papazafiropoulou, Marina S. Kardara and Stavros I. Pappas (2011). Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus, Diabetes - Damages and Treatments, Prof. Everlon Rigobelo (Ed.), ISBN: 978-953-307-652-2, InTech, Available from: http://www.intechopen.com/books/diabetes-damages-and-treatments/role-of-incretin-incretin-analogues-and-dipeptidyl-peptidase-4-inhibitors-in-the-pathogenesis-and-tr